靶向m6A阅读蛋白YTHDF1增强结直肠癌抗肿瘤免疫并提升抗PD-1疗效
该研究在组织芯片(N=408)和TCGA(N=526)队列中评估YTHDF1的临床意义,并通过同系肿瘤、肠道特异性Ythdf1敲入小鼠及人源化小鼠探究其功能。YTHDF1通过m6A-p65-CXCL1/CXCR2轴促进髓源性抑制细胞迁移、抑制CD8+ T细胞功能,从而损害抗肿瘤免疫;靶向YTHDF1可增强MSI-H结直肠癌的抗PD-1疗效并克服MSS结直肠癌的抗PD-1耐药。
要点
- YTHDF1表达与TCGA结直肠癌中干扰素-γ基因特征负相关,与CD8+ T细胞浸润负相关。
- Ythdf1敲除增强CT26(MSS-CRC)和MC38(MSI-H-CRC)同系肿瘤的抗肿瘤免疫。
- CRISPR或VNPs-siYTHDF1靶向YTHDF1可提升MSI-H CRC抗PD-1疗效并克服MSS CRC抗PD-1耐药。
核心结论
- YTHDF1通过m6A-p65-CXCL1/CXCR2轴损害抗肿瘤免疫以促进结直肠癌,并可作为免疫检查点阻断治疗的治疗靶点。
研究设计与样本
- 在组织芯片(N=408)和TCGA(N=526)队列中评估YTHDF1的临床意义。
- 在同系肿瘤、肠道特异性Ythdf1敲入小鼠及人源化小鼠中探究YTHDF1功能。
- 采用单细胞RNA测序(scRNA-seq)分析肿瘤免疫微环境(TIME)。
- 采用甲基化RNA免疫沉淀测序(MeRIP-seq)、RNA测序(RNA-seq)和核糖体测序(Ribo-seq)鉴定YTHDF1直接靶点。
- 使用囊泡样纳米颗粒(VNPs)包裹的YTHDF1-siRNA在体内沉默YTHDF1。
主要发现
- YTHDF1表达与TCGA-CRC中干扰素-γ基因特征负相关。
- YTHDF1蛋白与独立组织芯片队列中CD8+ T细胞浸润负相关。
- Ythdf1基因敲除增强CT26(MSS-CRC)和MC38(MSI-H-CRC)同系肿瘤的抗肿瘤免疫。
- Ythdf1敲入在氧化偶氮甲烷-硫酸葡聚糖钠或ApcMin/+模型中促进免疫抑制性TIME并促进CRC。
- scRNA-seq显示Ythdf1敲除肿瘤中髓源性抑制细胞(MDSCs)减少,同时细胞毒性T细胞增加。
关键数值与推荐
- 整合MeRIP-seq、RNA-seq和Ribo-seq揭示p65/Rela为YTHDF1靶点。
- YTHDF1促进p65翻译上调CXCL1,CXCL1通过CXCL1-CXCR2轴增加MDSC迁移。
- 增多的MDSCs反过来拮抗TIME中功能性CD8+ T细胞。
- 通过CRISPR或VNPs-siYTHDF1靶向YTHDF1可提升MSI-H CRC的抗PD-1疗效。
- 通过CRISPR或VNPs-siYTHDF1靶向YTHDF1可克服MSS CRC的抗PD-1耐药。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- YTHDF1在TIME中的作用此前尚未被充分研究,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The role of N6-methyladenosine (m6A) in tumour immune microenvironment (TIME) remains understudied. Here, we elucidate function and mechanism of YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) in colorectal cancer (CRC) TIME. DESIGN: Clinical significance of YTHDF1 was assessed in tissue microarrays (N=408) and TCGA (N=526) cohorts. YTHDF1 function was determined in syngeneic tumours, intestine-specific Ythdf1 knockin mice, and humanised mice. Single-cell RNA-seq (scRNA-seq) was employed to profile TIME. Methylated RNA immunoprecipitation sequencing (MeRIP-seq), RNA sequencing (RNA-seq) and ribosome sequencing (Ribo-seq) were used to identify YTHDF1 direct targets. Vesicle-like nanoparticles (VNPs)-encapsulated YTHDF1-siRNA was used for YTHDF1 silencing in vivo. RESULTS: YTHDF1 expression negatively correlated with interferon-γ gene signature in TCGA-CRC. Concordantly, YTHDF1 protein negatively correlated with CD8+ T-cell infiltration in independent tissue microarrays cohorts, implying its role in TIME. Genetic depletion of Ythdf1 augmented antitumour immunity in CT26 (MSS-CRC) and MC38 (MSI-H-CRC) syngeneic tumours, while Ythdf1 knockin promoted an immunosuppressive TIME facilitating CRC in azoxymethane-dextran sulphate-sodium or ApcMin/+ models. scRNA-seq identified reduction of myeloid-derived suppressor cells (MDSCs), concomitant with increased cytotoxic T cells in Ythdf1 knockout tumours. Integrated MeRIP-seq, RNA-seq and Ribo-seq revealed p65/Rela as a YTHDF1 target. YTHDF1 promoted p65 translation to upregulate CXCL1, which increased MDSC migration via CXCL1-CXCR2 axis. Increased MSDCs in turn antagonised functional CD8+ T cells in TIME. Importantly, targeting YTHDF1 by CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) or VNPs-siYTHDF1 boosted anti-PD1 efficacy in MSI-H CRC, and overcame anti-PD1 resistance in MSS CRC. CONCLUSION: YTHDF1 impairs antitumour immunity via an m6A-p65-CXCL1/CXCR2 axis to promote CRC and serves as a therapeutic target in immune checkpoint blockade therapy.
引用
- Bao Y, Zhai J, Chen H, et al. Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut. 2023. PMID: 36717220. doi:10.1136/gutjnl-2022-328845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。